TrialBMC cancer2014

Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients.

Gianmaria Miolo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.